Teh-Ia Huo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8235517/publications.pdf

Version: 2024-02-01

288 papers	8,030 citations	50276 46 h-index	76900 74 g-index
289 all docs	289 docs citations	289 times ranked	8265 citing authors

#	Article	IF	Citations
1	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. Journal of Hepatology, 2009, 51, 890-897.	3.7	369
2	Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology, 1998, 28, 231-236.	7.3	233
3	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. Journal of Hepatology, 2016, 64, 601-608.	3.7	220
4	Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology, 2013, 57, 112-119.	7.3	168
5	Gastrointestinal and liver manifestations in patients with COVID-19. Journal of the Chinese Medical Association, 2020, 83, 521-523.	1.4	165
6	Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet, The, 1995, 346, 939-941.	13.7	158
7	A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system. Journal of Hepatology, 2010, 53, 108-117.	3.7	157
8	Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas. Clinical Gastroenterology and Hepatology, 2011, 9, 79-86.	4.4	151
9	Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma â‰¤ 2â€Šcm in a Propensity Score Model. Annals of Surgery, 2016, 263, 538-545.	4.2	148
10	Gallic Acid Ameliorated Impaired Glucose and Lipid Homeostasis in High Fat Diet-Induced NAFLD Mice. PLoS ONE, 2014, 9, e96969.	2.5	143
11	Evaluation of the increase in model for end-stage liver disease (Î”MELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Childâ€“Turcotteâ€“Pugh score. Journal of Hepatology, 2005, 42, 826-832.	3.7	135
12	ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 879-886.	2.8	126
13	Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis. Annals of Surgical Oncology, 2012, 19, 842-849.	1.5	108
14	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. PLoS ONE, 2015, 10, e0120443.	2.5	105
15	Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver International, 2007, 27, 498-506.	3.9	96
16	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. Seminars in Liver Disease, 2018, 38, 242-251.	3.6	95
17	Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. Annals of Surgical Oncology, 2014, 21, 1825-1833.	1.5	93
18	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology, 2012, 56, 1097-1103.	3.7	91

#	Article	IF	Citations
19	Selecting an optimal staging system for hepatocellular carcinoma. Cancer, 2010, 116, 3006-3014.	4.1	88
20	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology, 2017, 285, 670-680.	7.3	88
21	Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene, 2001, 20, 3620-3628.	5.9	86
22	Selecting an optimal prognostic system for liver cirrhosis: the model for endâ€stage liver disease and beyond. Liver International, 2008, 28, 606-613.	3.9	77
23	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. PLoS ONE, 2013, 8, e72049.	2.5	76
24	Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transplantation, 2006, 12, 65-71.	2.4	74
25	Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 747-751.	2.8	72
26	Vascular Invasion in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2014, 48, 734-741.	2.2	68
27	METTL3-dependent N ⁶ -methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	68
28	The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS ONE, 2013, 8, e66457.	2.5	67
29	Outcome After Percutaneous Cholecystostomy for Acute Cholecystitis: a Single-Center Experience. Journal of Gastrointestinal Surgery, 2012, 16, 1860-1868.	1.7	66
30	The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey. American Journal of Gastroenterology, 2007, 102, 1920-1930.	0.4	65
31	Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. Biomaterials, 2011, 32, 5994-6005.	11.4	65
32	Diabetes Mellitus Is A Risk Factor for Hepatic Decompensation in Patients With Hepatocellular Carcinoma Undergoing Resection: A Longitudinal Study. American Journal of Gastroenterology, 2003, 98, 2293-2298.	0.4	63
33	Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis. Liver Transplantation, 2011, 17, 556-566.	2.4	63
34	Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Alimentary Pharmacology and Therapeutics, 2006, 23, 129-135.	3.7	61
35	Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver International, 2004, 24, 210-215.	3.9	60
36	Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. Clinical Transplantation, 2006, 20, 188-194.	1.6	60

#	Article	IF	Citations
37	Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatology International, 2010, 4, 691-699.	4.2	60
38	Differential Mechanism and Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma Undergoing Surgical and Nonsurgical Treatment. American Journal of Gastroenterology, 2004, 99, 1479-1487.	0.4	58
39	A new ALBIâ€based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver International, 2019, 39, 1704-1712.	3.9	58
40	Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy. Journal of Clinical Gastroenterology, 2012, 46, 62-70.	2.2	56
41	The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer, 2006, 107, 141-148.	4.1	54
42	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy. European Journal of Gastroenterology and Hepatology, 2011, 23, 1.	1.6	53
43	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Annals of Surgical Oncology, 2016, 23, 874-883.	1.5	51
44	Comparison of four model for end-stage liver diseaseâ€"based prognostic systems for cirrhosis. Liver Transplantation, 2008, 14, 837-844.	2.4	50
45	Liver Failure After Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma and Ascites. Journal of Clinical Gastroenterology, 2011, 45, 556-562.	2.2	49
46	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. International Journal of Cancer, 2013, 133, 2895-2902.	5.1	49
47	Injection with nondisposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan. Journal of Medical Virology, 1995, 46, 247-251.	5.0	48
48	The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: A prospective survey. Digestive and Liver Disease, 2008, 40, 882-889.	0.9	48
49	Oncogenic circRNA C190 Promotes Nonâ€"Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway. Cancer Research, 2022, 82, 75-89.	0.9	48
50	Proposal of a Modified Cancer of the Liver Italian Program Staging System Based on the Model for End-Stage Liver Disease for Patients with Hepatocellular Carcinoma Undergoing Loco-Regional Therapy. American Journal of Gastroenterology, 2006, 101, 975-982.	0.4	47
51	Diabetes Mellitus as a Risk Factor of Liver Cirrhosis in Patients With Chronic Hepatitis B Virus Infection. Journal of Clinical Gastroenterology, 2000, 30, 250-254.	2.2	45
52	Is the Corrected-Creatinine Model for End-Stage Liver Disease a Feasible Strategy to Adjust Gender Difference in Organ Allocation for Liver Transplantation?. Transplantation, 2007, 84, 1406-1412.	1.0	44
53	Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and longâ€term outcome. Alimentary Pharmacology and Therapeutics, 2004, 19, 999-1007.	3.7	43
54	Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clinical Radiology, 2012, 67, 429-436.	1.1	42

#	Article	IF	Citations
55	Synergistic effects of carboxymethyl-hexanoyl chitosan, cationic polyurethane-short branch PEI in miR122 gene delivery: Accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved stem cell therapy in a hepatic failure model. Acta Biomaterialia, 2015, 13, 228-244.	8.3	41
56	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer, 2016, 63, 25-33.	2.8	40
57	Dual Delivery of HNF4Î± and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells. ACS Applied Materials & Interfaces, 2019, 11, 19808-19818.	8.0	40
58	Prospective Case-controlled Trial of Adjuvant Chemotherapy after Resection of Hepatocellular Carcinoma. World Journal of Surgery, 2000, 24, 551-555.	1.6	39
59	Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study. Annals of Surgical Oncology, 2016, 23, 994-1002.	1.5	38
60	Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. European Journal of Surgical Oncology, 2019, 45, 776-781.	1.0	38
61	Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigenâ€negative chronic hepatitis B patients in Taiwan. Journal of Viral Hepatitis, 2003, 10, 277-284.	2.0	37
62	Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Scientific Reports, 2016, 6, 29605.	3.3	37
63	Validation of the albuminâ€bilirubin gradeâ€based integrated model as a predictor for sorafenibâ€failed hepatocellular carcinoma. Liver International, 2018, 38, 321-330.	3.9	37
64	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS ONE, 2016, 11, e0155588.	2.5	37
65	Correlation and Comparison of the Model for End-stage Liver Disease, Portal Pressure, and Serum Sodium for Outcome Prediction in Patients With Liver Cirrhosis. Journal of Clinical Gastroenterology, 2007, 41, 706-712.	2.2	36
66	Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatology International, 2013, 7, 188-198.	4.2	36
67	Using Serum Î±-Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff?. PLoS ONE, 2015, 10, e0118825.	2.5	36
68	Percutaneous Ablation Therapy for Hepatocellular Carcinoma: Current Practice and Future Perspectives. Journal of the Chinese Medical Association, 2005, 68, 155-159.	1.4	35
69	Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver International, 2006, 26, 55-61.	3.9	35
70	Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Digestive and Liver Disease, 2010, 42, 137-142.	0.9	35
71	Validation of the HCCâ€MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clinical Transplantation, 2008, 22, 469-475.	1.6	34
72	Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver International, 2010, 30, 77-84.	3.9	34

#	Article	IF	Citations
73	The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage. Alimentary Pharmacology and Therapeutics, 2005, 21, 687-694.	3.7	33
74	Radiofrequency Ablation is Better Than Surgical Resection in Patients With Hepatocellular Carcinoma Within the Milan Criteria and Preserved Liver Function. Journal of Clinical Gastroenterology, 2015, 49, 242-249.	2.2	33
75	Prognosis of Early-Stage Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1929.	1.0	32
76	Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS ONE, 2017, 12, e0180408.	2.5	31
77	Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. European Journal of Gastroenterology and Hepatology, 2003, 15, 1203-1208.	1.6	30
78	Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver International, 2010, 30, 198-207.	3.9	30
79	Enhanced Antioxidant Capacity of Dental Pulp-Derived iPSC-Differentiated Hepatocytes and Liver Regeneration by Injectable HGF-Releasing Hydrogel in Fulminant Hepatic Failure. Cell Transplantation, 2015, 24, 541-559.	2.5	30
80	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. Medicine (United States), 2015, 94, e688.	1.0	30
81	Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. Journal of the Formosan Medical Association, 2016, 115, 764-772.	1.7	30
82	Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score. PLoS ONE, 2018, 13, e0208903.	2.5	30
83	Survival Benefit of Cirrhotic Patients with Hepatocellular Carcinoma Treated by Percutaneous Ethanol Injection as a Salvage Therapy. Scandinavian Journal of Gastroenterology, 2002, 37, 350-355.	1.5	29
84	Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. Journal of Medical Virology, 2004, 72, 41-45.	5.0	29
85	Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency. Journal of Clinical Gastroenterology, 2010, 44, e171-e177.	2.2	29
86	Deterioration of Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma after Resection: Incidence, Risk Factors, and Association with Intrahepatic Tumor Recurrence. World Journal of Surgery, 2004, 28, 258-262.	1.6	28
87	Comparative Analysis of Noninvasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2011, 45, 278-285.	2.2	28
88	Albuminâ€bilirubin gradeâ€based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver International, 2020, 40, 205-214.	3.9	28
89	Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. Annals of Oncology, 2003, 14, 1648-1653.	1.2	27
90	Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: Is there a lead-time bias?. Scandinavian Journal of Gastroenterology, 2007, 42, 485-492.	1.5	27

#	Article	IF	Citations
91	The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer, 2018, 7, 335-358.	7.7	27
92	Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. Journal of Hepatology, 1996, 25, 439-444.	3.7	26
93	Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria. World Journal of Surgery, 2013, 37, 1348-1355.	1.6	26
94	When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?. Medicine (United States), 2015, 94, e1808.	1.0	26
95	The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis. PLoS ONE, 2015, 10, e0124654.	2.5	26
96	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Scientific Reports, 2018, 8, 4773.	3.3	26
97	IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B. PLoS ONE, 2013, 8, e58071.	2.5	26
98	Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. Journal of Viral Hepatitis, 2006, 13, 336-342.	2.0	25
99	Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2009, 43, 876-883.	2.2	25
100	Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 111, 404-409.	1.7	25
101	Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver International, 2016, 36, 1498-1506.	3.9	25
102	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Scientific Reports, 2017, 7, 42577.	3.3	25
103	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Scientific Reports, 2018, 8, 843.	3.3	25
104	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. Journal of the Chinese Medical Association, 2017, 80, 125-132.	1.4	24
105	Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. Alimentary Pharmacology and Therapeutics, 2004, 19, 1301-1308.	3.7	23
106	Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a followâ€up study up to 18 years. Liver International, 2008, 28, 1305-1313.	3.9	23
107	Î±-Fetoprotein-to-Total Tumor Volume Ratio Predicts Post-operative Tumor Recurrence in Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 730-738.	1.7	23
108	Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. Annals of Oncology, 2004, 15, 775-780.	1.2	22

#	Article	IF	Citations
109	The First Case of Multidrug-resistant NDM-1-harboring Enterobacteriaceae in Taiwan: Here Comes the Superbacteria!. Journal of the Chinese Medical Association, 2010, 73, 557-558.	1.4	22
110	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology, 2019, 69, 1151-1164.	7.3	22
111	Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transplantation, 2004, 10, 1507-1513.	2.4	21
112	Different Model for End-Stage Liver Disease Score Block Distributions May Have a Variable Ability for Outcome Prediction. Transplantation, 2005, 80, 1414-1418.	1.0	21
113	Selecting a Short-term Prognostic Model for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2009, 43, 773-781.	2.2	21
114	Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clinical Nutrition, 2011, 30, 647-652.	5.0	21
115	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma. Medicine (United States), 2015, 94, e1772.	1.0	21
116	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3196-3203.	2.8	21
117	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International, 2012, 6, 753-762.	4.2	20
118	Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma. Medicine (United States), 2014, 93, e264.	1.0	20
119	ALBI grade as a new player in hepatocellular carcinoma. Journal of the Chinese Medical Association, 2019, 82, 1.	1.4	20
120	Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network. Nucleic Acids Research, 2019, 47, 10115-10133.	14.5	20
121	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver International, 2020, 40, 2522-2534.	3.9	20
122	Active Vitamin D₃ Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. Molecular Nutrition and Food Research, 2021, 65, e2000937.	3.3	20
123	Diagnostic value of antiâ€hepatitis D virus (HDV) antibodies revisited: A study of total and IgM antiâ€HDV compared with detection of HDVâ€RNA by polymerase chain reaction. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 57-61.	2.8	19
124	Hepatitis C Virus Infection is a Risk Factor for Tumor Recurrence after Resection of Small Hepatocellular Carcinomas. World Journal of Surgery, 2004, 28, 787-791.	1.6	19
125	Staging for hepatocellular carcinoma: look for a perfect classification system. Journal of Hepatology, 2004, 40, 1041-1042.	3.7	19
126	Characteristics and outcome of patients with dual hepatitis B and Câ€associated hepatocellular carcinoma: are they different from patients with single virus infection?. Liver International, 2009, 29, 767-773.	3.9	19

#	Article	IF	Citations
127	Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2012, 46, 789-795.	2.2	19
128	Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria. Annals of Surgical Oncology, 2014, 21, 3835-3843.	1.5	19
129	Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer, 2018, 18, 289.	2.6	19
130	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. Journal of the Formosan Medical Association, 2020, 119, 218-229.	1.7	19
131	Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncology Reports, 2004, 11, 543-50.	2.6	19
132	Improvement of Carbon Tetrachloride-Induced Acute Hepatic Failure by Transplantation of Induced Pluripotent Stem Cells without Reprogramming Factor c-Myc. International Journal of Molecular Sciences, 2012, 13, 3598-3617.	4.1	18
133	CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study. PLoS ONE, 2013, 8, e76798.	2.5	18
134	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. Annals of Hepatology, 2013, 12, 263-273.	1.5	18
135	Pharmacokinetics of Ractopamine and Its Organ Distribution in Rats. Journal of Agricultural and Food Chemistry, 2014, 62, 9273-9278.	5.2	18
136	Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. Journal of Gastrointestinal Surgery, 2014, 18, 1623-1631.	1.7	18
137	Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. Annals of Surgical Oncology, 2015, 22, 1324-1331.	1.5	18
138	Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. Liver International, 2018, 38, 1803-1811.	3.9	18
139	Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. Scientific Reports, 2020, 10, 3925.	3.3	18
140	The Sequential Changes of the Model for End-stage Liver Disease Score Correlate With the Severity of Liver Cirrhosis in Patients With Hepatocellular Carcinoma Undergoing Locoregional Therapy. Journal of Clinical Gastroenterology, 2006, 40, 543-550.	2.2	17
141	Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatology International, 2013, 7, 645-654.	4.2	17
142	Performance Status Enhances the Selection of Treatment for Patients with Hepatocellular Carcinoma Within the Milan Criteria. Annals of Surgical Oncology, 2013, 20, 2035-2042.	1.5	17
143	A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Childâ€“Pugh Scores of 5 or 6. Medicine (United States), 2014, 93, e348.	1.0	17
144	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 238-238.	1.7	17

#	Article	IF	Citations
145	Easy albuminâ€“bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatology Research, 2021, 51, 1129-1138.	3.4	17
146	A New Tumor Burden Score and Albuminâ€“Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers, 2022, 14, 649.	3.7	17
147	Kidney transplantation in patients with chronic hepatitis B virus infection: is the prognosis worse?. Digestive Diseases and Sciences, 2001, 46, 469-475.	2.3	16
148	An Albumin-Bilirubin (ALBI) Gradeâ€“based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 698-704.	1.3	15
149	Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. PLoS ONE, 2017, 12, e0174333.	2.5	14
150	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. Gastroenterology Research and Practice, 2017, 2017, 1-12.	1.5	14
151	A New Prognostic Model Based on Albuminâ€“Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Digestive Diseases and Sciences, 2020, 65, 658-667.	2.3	14
152	Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. Journal of the Formosan Medical Association, 2021, 120, 1563-1571.	1.7	14
153	Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS ONE, 2017, 12, e0188031.	2.5	14
154	Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 1138-1142.	2.8	13
155	Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 1187-1191.	2.8	13
156	Model for End-stage Liver Disease and Organ Allocation in Liver Transplantation: Where Are We and Where Should We Go?. Journal of the Chinese Medical Association, 2006, 69, 193-198.	1.4	13
157	Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatology International, 2011, 5, 975-984.	4.2	13
158	Induced pluripotent stem cells and hepatic differentiation. Journal of the Chinese Medical Association, 2013, 76, 599-605.	1.4	13
159	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. European Radiology, 2017, 27, 2600-2609.	4.5	13
160	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association, 2020, 119, 610-620.	1.7	13
161	(Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-Î²1/SMAD3 Pathway. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 813-838.	4.5	13
162	Decrypting Cryptogenic Hepatocellular Carcinoma: Clinical Manifestations, Prognostic Factors and Long-Term Survival by Propensity Score Model. PLoS ONE, 2014, 9, e89373.	2.5	13

#	Article	IF	Citations
163	Prognostic factor analysis of fulminant and subfulminant hepatic failure in an area endemic for hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 560-565.	2.8	12
164	Prevalence, implication, and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. , 1998, 56, 118-122.		12
165	Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: A report of two cases. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 481-483.	2.8	12
166	Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 690-699.	2.8	12
167	Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury. Cells, 2021, 10, 1562.	4.1	12
168	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Annals of Hepatology, 2015, 14, 181-9.	1.5	12
169	MELD in liver transplantation: the da Vinci code for the Holy Grail?. Journal of Hepatology, 2005, 42, 477-478.	3.7	11
170	The predictive ability of serum Î±-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. Journal of Surgical Oncology, 2007, 95, 645-651.	1.7	11
171	Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1581-1588.	2.8	11
172	A prognostic model for patients with hepatocellular carcinoma within the <scp>M</scp>ilan criteria undergoing nonâ€transplant therapies, based on 1106 patients. Alimentary Pharmacology and Therapeutics, 2012, 36, 551-559.	3.7	11
173	Hepatocellular carcinoma in uremic patients: Is there evidence for an increased risk of mortality?. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 348-356.	2.8	11
174	Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. Medicine (United States), 2015, 94, e1223.	1.0	11
175	The Role of Interferon-Î³ Inducible Protein-10 in a Mouse Model of Acute Liver Injury Post Induced Pluripotent Stem Cells Transplantation. PLoS ONE, 2012, 7, e50577.	2.5	11
176	Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of Î±-fetoprotein. Liver International, 2010, 30, 1161-1168.	3.9	10
177	Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Digestive and Liver Disease, 2012, 44, 868-874.	0.9	10
178	Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers, 2020, 12, 1130.	3.7	10
179	Albuminâ€“Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Digestive Diseases and Sciences, 2021, 66, 1730-1738.	2.3	10
180	The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 117-124.	2.5	9

#	Article	IF	Citations
181	Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis. Digestive Diseases and Sciences, 2021, 66, 4508-4517.	2.3	9
182	Staging for hepatocellular carcinoma: Treatment strategy matters. Hepatology, 2005, 41, 678-678.	7.3	8
183	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. PLoS ONE, 2014, 9, e99115.	2.5	8
184	Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Scientific Reports, 2018, 8, 15074.	3.3	8
185	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer, 2023, 54, 420-432.	1.3	8
186	Persistent retention of acetic acid is associated with complete tumour necrosis in patients with hepatocellular carcinoma undergoing percutaneous acetic acid injection. Scandinavian Journal of Gastroenterology, 2004, 39, 168-173.	1.5	7
187	Selective prognostic impact of serum Î±-fetoprotein level in patients with hepatocellular carcinoma: Analysis of 543 patients in a single center. Oncology Reports, 2004, 11, 543.	2.6	7
188	Fever and Infectious Complications After Percutaneous Acetic Acid Injection Therapy for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis. Journal of Clinical Gastroenterology, 2006, 40, 639-642.	2.2	7
189	Hepatitis after arterial embolization for hepatocellular carcinoma: Viral reactivation or ischemia?. Hepatology, 2006, 43, 1400-1401.	7.3	7
190	Major adverse events, pretransplant assessment and outcome prediction. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1716-1724.	2.8	7
191	Selecting an optimal cutoff value for creatinine in the model for endâ€stage liver disease equation. Clinical Transplantation, 2010, 24, 157-163.	1.6	7
192	Core Antigen Expression Is Associated with Hepatic Necroinflammation in e Antigen-Negative Chronic Hepatitis B Patients with Low DNA Loads. Vaccine Journal, 2010, 17, 1048-1053.	3.1	7
193	Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2018, 30, 1368-1377.	1.6	7
194	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Scientific Reports, 2020, 10, 17259.	3.3	7
195	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. Scientific Reports, 2020, 10, 2006.	3.3	7
196	Reliability of contemporary radiology to measure tumour size of hepatocellular carcinoma in patients undergoing resection: limitations and clinical implications. Scandinavian Journal of Gastroenterology, 2004, 39, 46-52.	1.5	6
197	Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. European Journal of Gastroenterology and Hepatology, 2004, 16, 325-331.	1.6	6
198	Is there an ideal prognostic model for hepatocellular carcinoma?. Gut, 2005, 54, 1348-1348.	12.1	6

#	Article	IF	Citations
199	Metastatic hepatocellular carcinoma: when, how, where and so what?. Liver International, 2008, 28, 1183-1185.	3.9	6
200	Validation of the behavior and concept based assessment of professionalism competence in postgraduate first-year residents. Journal of the Chinese Medical Association, 2013, 76, 186-194.	1.4	6
201	Assessing liver dysfunction in cirrhosis: Role of the model for end-stage liver disease and its derived systems. Journal of the Chinese Medical Association, 2013, 76, 419-424.	1.4	6
202	2'â€Hydroxyflavanone ameliorates mesenteric angiogenesis and portalâ€systemic collaterals in rats with liver fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1045-1051.	2.8	6
203	A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma. Scientific Reports, 2017, 7, 7914.	3.3	6
204	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS ONE, 2017, 12, e0188552.	2.5	6
205	Development of a Graphene Oxide-Incorporated Polydimethylsiloxane Membrane with Hexagonal Micropillars. International Journal of Molecular Sciences, 2018, 19, 2517.	4.1	6
206	Nanodiamond-based microRNA delivery system promotes pluripotent stem cells toward myocardiogenic reprogramming. Journal of the Chinese Medical Association, 2021, 84, 177-182.	1.4	6
207	Nomogram for surgical hepatocellular carcinoma: What have we missed?. Liver International, 2021, 41, 3034-3035.	3.9	5
208	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albuminâ€“bilirubin grade. International Journal of Clinical Oncology, 2022, 27, 739-748.	2.2	5
209	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. Scientific Reports, 2022, 12, 8343.	3.3	5
210	Management of inoperable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, S272-S278.	2.8	4
211	Cholestatic Jaundice as the Predominant Presentation in a Patient with Autoimmune Hepatitis. Journal of the Chinese Medical Association, 2008, 71, 45-48.	1.4	4
212	Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification. Journal of Hepatology, 2009, 50, 779-788.	3.7	4
213	Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 192-198.	2.8	4
214	Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes. Clinical Science, 2018, 132, 2391-2405.	4.3	4
215	Diabetes Diminishes the Portal-Systemic Collateral Vascular Response to Vasopressin via Vasopressin Receptor and GÎ± Proteins Regulations in Cirrhotic Rats. PLoS ONE, 2013, 8, e67703.	2.5	4
216	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. American Journal of Cancer Research, 2021, 11, 3711-3725.	1.4	4

#	Article	IF	Citations
217	Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scandinavian Journal of Gastroenterology, 2023, 58, 61-69.	1.5	4
218	Contrast medium-associated renal dysfunction in patients with cirrhosis. Hepatology, 2004, 40, 1474-1474.	7.3	3
219	Is diabetes a risk factor for hepatocellular carcinoma?. Gastroenterology, 2004, 127, 360-361.	1.3	3
220	Role of the model for end-stage liver disease and serum ?-fetoprotein as prognostic predictors for hepatocellular carcinoma. Liver International, 2006, 26, 1300-1301.	3.9	3
221	Interleukinâ€1 receptor antagonist correlates with hepatic venous pressure gradient and predicts occurrence of overall complications and bacterial infections in patients with cirrhosis. Hepatology Research, 2015, 45, 294-304.	3.4	3
222	Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4. Journal of Clinical Gastroenterology, 2015, 49, 878-884.	2.2	3
223	Reply to â€œHepatocellular carcinoma scoring and staging systems. Do we need new tools?â€. Journal of Hepatology, 2016, 64, 1450-1452.	3.7	3
224	Performance status in patients with HCC: New kid on the block. Journal of Hepatology, 2017, 67, 1352-1353.	3.7	3
225	Pharmacokinetics of Rhodamine 110 and Its Organ Distribution in Rats. Journal of Agricultural and Food Chemistry, 2017, 65, 7797-7804.	5.2	3
226	Ascorbate lacks significant influence in rats with bile duct ligation-induced liver injury. Journal of the Chinese Medical Association, 2017, 80, 539-550.	1.4	3
227	Magic mirror on the wall: Which is the best biomarker for hepatocellular carcinoma?. Hepatology, 2018, 67, 2482-2483.	7.3	3
228	Microvascular Invasion as a Prognostic Predictor in Hepatocellular Carcinoma: How Accurate Is It?. Liver Cancer, 2020, 9, 787-788.	7.7	3
229	Changing faces of hepatocellular carcinoma: East vs West. Liver International, 2021, 41, 1430-1431.	3.9	3
230	To MELD or not to MELD, that is a question. Liver Transplantation, 2007, 13, 1618-1618.	2.4	2
231	Lack of therapeutic effects of gabexate mesilate on the hepatic encephalopathy in rats with acute and chronic hepatic failure. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1321-1328.	2.8	2
232	The Global Spread of 2009 H1N1 Influenza: A False Pandemic?. Journal of the Chinese Medical Association, 2010, 73, 60-61.	1.4	2
233	Diabetes enhances the intrahepatic vascular response to endothelinâ€1 in cirrhotic rats: association with the ET_A receptor and <scp>pERK</scp> upâ€regulation. Liver International, 2015, 35, 704-712.	3.9	2
234	Nomogram of the Barcelona clinic liver cancer system: on the go. Liver International, 2016, 36, 1717-1718.	3.9	2

#	Article	IF	Citations
235	Treating Very Early-stage HCC. Annals of Surgery, 2017, 266, e31-e32.	4.2	2
236	Comment on â€˜Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasionâ€™. British Journal of Cancer, 2017, 117, e5-e5.	6.4	2
237	ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Is It Sufficient. Liver Cancer, 2017, 6, 375-376.	7.7	2
238	Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?. Journal of Hepatology, 2018, 68, 862-863.	3.7	2
239	Folic acid ameliorates homocysteine-induced angiogenesis and portosystemic collaterals in cirrhotic rats. Annals of Hepatology, 2019, 18, 633-639.	1.5	2
240	Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2020, 32, 365-372.	1.6	2
241	Are inflammationâ€based models feasible tools in predicting the outcome of patients with hepatocellular carcinoma?. Liver International, 2020, 40, 1498-1498.	3.9	2
242	Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic. Journal of the Chinese Medical Association, 2020, 83, 809-811.	1.4	2
243	Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors. Journal of Hepatology, 2020, 72, 1032-1033.	3.7	2
244	Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. Digestive Diseases and Sciences, 2020, 65, 3389-3402.	2.3	2
245	Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. Journal of the Chinese Medical Association, 2021, 84, 472-477.	1.4	2
246	Predicting microvascular invasion in HCC with ctDNA: What are the pitfalls?. Liver International, 2021, 41, 1148-1149.	3.9	2
247	Role of locoregional therapy for hepatocellular carcinoma before liver transplantation: Answer or myth?. Liver Transplantation, 2006, 12, 1560-1560.	2.4	1
248	Successful Radiofrequency Ablation Therapy for Hepatocellular Carcinoma in a Male Patient with Early Stage Primary Biliary Cirrhosis and Positive Serum Hepatitis B Core Antibody. Journal of the Chinese Medical Association, 2008, 71, 40-44.	1.4	1
249	Utility of prognostic scoring systems in management of hepatocellular carcinoma. European Journal of Cancer, 2016, 68, 206-207.	2.8	1
250	Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs. ALBI grade. Journal of Hepatology, 2019, 70, 808.	3.7	1
251	Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?. Liver Cancer, 2020, 9, 108-109.	7.7	1
252	Metavir Fibrosis Stage in Hepatitis Câ€“Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models. Journal of Gastrointestinal Surgery, 2020, 24, 1860-1862.	1.7	1

#	Article	IF	Citations
253	Treating Small Hepatocellular Carcinoma: Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2020-2020.	2.8	1
254	Changing patterns of etiology and management of hepatocellular carcinoma: need for global reappraisal. Journal of Gastroenterology, 2021, 56, 406-407.	5.1	1
255	ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. Journal of Gastrointestinal Oncology, 2021, 12, 722-734.	1.4	1
256	Dual DNA Transfection Using 1,6-Hexanedithiol-Conjugated Maleimide-Functionalized PU-PEI600 For Gene Correction in a Patient iPSC-Derived Fabry Cardiomyopathy Model. Frontiers in Cell and Developmental Biology, 2021, 9, 634190.	3.7	1
257	Selecting an optimal prognostic model for advanced hepatocellular carcinoma: Any new ideas?. Digestive and Liver Disease, 2021, 53, 1208-1209.	0.9	1
258	Outstanding research paper awards of the Journal of the Chinese Medical Association in 2020. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .	1.4	1
259	Development of polydimethylsiloxane-based biomimetic scaffolds with cylinder micropillars for retinal pigment epithelial cell cultivation. Journal of the Chinese Medical Association, 2020, 83, 1029-1033.	1.4	1
260	Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?. Journal of Hepatology, 2021, , .	3.7	1
261	Long-term outcome of kidney transplantation in patients with hepatitis C virus infection. Hepato-Gastroenterology, 2001, 48, 169-73.	0.5	1
262	<scp>3â€Mercaptopyruvate</scp> sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor?. Liver International, 2022, 42, 1475-1475.	3.9	1
263	Does antibody to hepatitis B surface antigen protect renal transplant patients from hepatitis B?. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 841-843.	2.8	0
264	Which is the holy grail in liver transplantation: Hyponatremia, MELD, or a combination?. Liver Transplantation, 2005, 11, 710-710.	2.4	0
265	Does hepatitis B viral load determine the outcome of patients with hepatocellular carcinoma undergoing chemotherapy?. Hepatology, 2007, 46, 1665-1666.	7.3	0
266	Transarterial chemoembolization and renal failure in hepatocellular carcinoma patients: authors' reply. Liver International, 2010, 30, 924-925.	3.9	0
267	Commentary: predicting survival in hepatocellular carcinoma patients â€“ authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 681-681.	3.7	0
268	Surgery for advanced hepatocellular carcinoma: Time to take action. Journal of Surgical Oncology, 2015, 112, 909-909.	1.7	0
269	Ablation for Hepatocellular Carcinoma. Annals of Surgery, 2017, 266, e55-e56.	4.2	0
270	The effects of proton pump inhibitor on hepatic vascular responsiveness and hemodynamics in cirrhotic rats. Journal of the Chinese Medical Association, 2018, 81, 585-592.	1.4	0

#	Article	IF	Citations
271	Comparison of twelve noninvasive liver reserve models in HCC patients undergoing resection. Journal of Hepatology, 2018, 68, S640.	3.7	0
272	The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S713.	3.7	0
273	Correlation and prognostic accuracy between noninvasive liver reserve markers and portal pressure in cirrhosis: Role of ALBI score. Journal of Hepatology, 2018, 68, S736-S737.	3.7	0
274	SAT-462-Current non-invasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e836-e837.	3.7	0
275	SAT-463-Albumin-bilirubin grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e837-e838.	3.7	0
276	Staging and Restaging for Hepatocellular Carcinoma: Solution of Confusion?. Hepatology, 2019, 69, 464-465.	7.3	0
277	Evolution of hepatocellular carcinoma: non-B, non-C and beyond. Journal of Gastroenterology, 2020, 55, 123-124.	5.1	0
278	Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers. Journal of Hepatology, 2020, 73, 972-973.	3.7	0
279	Is computed tomographyâ€enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma?. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2289-2289.	2.8	0
280	Tumour burden score for hepatocellular carcinoma: Is it an authentic prognostic marker?. British Journal of Surgery, 2020, 107, e625-e625.	0.3	0
281	Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations. Hepatology, 2021, 73, 2611-2611.	7.3	0
282	Post hepatitis Bâ€eliminated hepatocellular carcinoma: New challenges. Liver International, 2021, 41, 1173-1174.	3.9	0
283	Improved patient survival in hepatitis C virusâ€related hepatocellular carcinoma: Do directâ€acting antivirals play a role?. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	2.8	0
284	Hepatitis B and Hepatocellular Carcinoma and Their Treatment. , 2012, , 119-141.		0
285	Comment on â€œEffect of Microvascular Invasion Risk on Early Recurrence of Hepatocellular Carcinoma After Surgery and Radiofrequency Ablationâ€. Annals of Surgery, 2021, 274, e101-e102.	4.2	0
286	Improving the accuracy of outcome prediction for <scp>hepatocellular carcinoma</scp>: Asia strategies. Liver International, 2022, 42, 714-715.	3.9	0
287	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. American Journal of Cancer Research, 2021, 11, 5526-5542.	1.4	0
288	Look for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0